logo
Share SHARE
FONT-SIZE Plus   Neg

DENTSPLY Int'l. Q1 GAAP Profit Slips, Adj. EPS Up - Quick Facts

DENTSPLY International Inc. (XRAY) posted lower first-quarter net income attributable to the company of $53.3 million, or $0.37 per share, compared with $69.1 million, or $0.48 per share in the prior-year quarter.

However, excluding non-GAAP items, quarterly adjusted earnings per share were $0.52, higher than $0.50 a year earlier. On average, 14 analysts polled by Thomson Reuters expected earnings per share of $0.52 for the quarter. Analysts' estimates typically exclude one-time items.

Net sales in the recent quarter increased 25.6% to $716.4 million from $570.5 million last year, whereas 10 analysts estimated revenues of $718.72 million for the quarter. Net sales, excluding precious metals content, of $665.6 million went up 26.3% from $527.0 million in the first quarter of 2011. Constant currency net sales growth, excluding precious metals content, was 28.3%, driven largely by acquisitions, but also supported by internal sales growth, which was notably strong in the U.S.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Snack and beverage giant Pepsico Inc. reported Thursday significantly higher profit in its third quarter, reflecting the absence of last year's hefty Venezuelan impairment charges, despite weak revenues. Core earnings and revenues beat market estimates. Further, the company lifted its fiscal 2016 forecast on its performance and outlook for the fourth quarter. Almost 71 percent of Americans say they don't save enough for their retirement, while around 54 percent believe they will never pay off their debt fully, according to a new national survey. The latest survey, commissioned by Experian together with Get Rich Slowly and other top U.S. personal finance... The biotech space is not for the faint hearted, given the ebbs and flows in terms of the returns from investing in it. However, for one who perseveres and astutely devises strategies with full cognizance of key regulatory events coming up, the probability of drug candidates getting FDA's blessings and sympathy plays in the space, it provides a sea of opportunity and huge upside prospects.
comments powered by Disqus
Follow RTT